KIT and neoplasm: As the majority of resistance mechanisms to BRAFi + MEKi are related to the MAPK pathway [11,22], we may assume that this baseline tumor-suppressor effect of KIT is emphasized in our cohort, improving the clinical course under BRAFi + MEKi.